Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Commentary|Articles|June 30, 2026
Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?
Author(s)Joseph F. Goldberg, MD, Roy Perlis, MD
AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.
Advertisement
Advertisement
BRAIN TRUST: CONVERSATIONS IN PSYCHOPHARMACOLOGY
Related to this article
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Per capita state suicide prevention funding rose 6-fold from 2021 to 2025 and was more than double in states with 988 telecom fees, study finds.
Advertisement
Advertisement